Externally Developed Products Mean Bigger Revenues, But Not In Diabetes
External innovation directly links to commercial success for big pharma, and will continue to do so until 2026, according to a new report by Datamonitor Healthcare.
You may also be interested in...
Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.
Sanofi’s diabetes head says French drug maker’s JV pact with Google’s Verily will combine novel therapies for the condition with cutting edge technologies to produce better focused, outcome-based combinations.
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.